Enterprise Strategy

We have three aims at LISCB that underpin our enterprise strategy, and allow us to identify priority projects and provide targeted support to enhance the progression of these projects with existing industry partners.

  1. Organising and hosting events for building staff engagement and garnering an understanding of industry interactions
  2. Creation of platforms to cultivate new industry relations
  3. LISCB systems to anticipate potential industry collaboration within our research plans

Essential Enterprise

The aim of Essential Enterprise is to help our Institute staff build an understanding of industry collaboration. This is achieved by:

  • Presentations both from peers who are already collaborating with industry, and from the companies themselves.
  • Information is provided on the changing landscape of UK research funding and the wide array of new opportunities and schemes related to industry funding.

This initiative was Established in March 2017 and now has been embedded into a rolling programme through the year. The inaugural sessions included presentations from Sygnature, LifeArc and AstraZeneca.

Bench 2 Business

The aim of this initiative is provide a series of touchpoints for our academics to engage with industry.  The first Bench 2 Business event was held in May 2017 and was funded by the MRC Proximity to Discovery award to the University. At the event:

  • LISCB hosted commercial partners to allow us to demonstrate our capabilities, expertise and facilities.
  • The event was an opportunity to showcase the Institute to potential partners, more broadly through the production of a brochure specifically tailored to industry.

Leicester Splicing and Epigenetics Club

In November 2017 we launched the Leicester Splicing and Epigentics club, an academic / industry forum between pharmaceutical companies and the members of the Institute. With the aim of the club being:

  • To provide a focus point for companies with a particular interest in splicing to discuss current challenges and future needs in this area
  • An opportunity for companies to learn about the latest scientific advances in the field by accessing Institute members expertise
  • Enhancing LISCB's efficiency and collaboration capabilities in future academic research as companies will be able to provide feedback

Enterprise Highlights

  • Establishing an Antibody-Assisted Structure-Based Drug Discovery collaboration between the laboratory of Mark Carr with UCB and LifeArc. The aim of the project is to use antibodies as tools to identify and characterise novel regulatory or allosteric sites on therapeutic target proteins. The Unique knowledge gained by this approach will be utilised to guide the discovery and design of novel small molecule therapeutics.
  • Collaboration of the LISCB pairing Cyril Dominguez and Ian Eperon with the European Lead Factory (ELF) to progress a high-throughput screening project. This proof-of-principle study demonstrates that it is possible to identify small molecules that interfere with the RNA binding properties of splicing factors to bring opportunities for the development of novel therapeutic treatments against various cancers, and other diseases.
  • John Schwabe was part of the UoL team, led by Professor Simon Wagner (Department of Cancer Studies) which was awarded one of seven Discovery Partnerships with Academia (DPAc) awards from GSK to discovered and develop novel medicines to treat aggressive forms of blood cancer.